Detalhe da pesquisa
1.
Mesenchymal stromal cell senescence in haematological malignancies.
Cancer Metastasis Rev;
42(1): 277-296, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36622509
2.
Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma.
Br J Haematol;
203(4): 614-624, 2023 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37699574
3.
Macrophages in multiple myeloma: key roles and therapeutic strategies.
Cancer Metastasis Rev;
40(1): 273-284, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33404860
4.
A niche-dependent myeloid transcriptome signature defines dormant myeloma cells.
Blood;
134(1): 30-43, 2019 07 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31023703
5.
Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo
Haematologica;
106(12): 3176-3187, 2021 Dec 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33147936
6.
Seed and soil revisited in multiple myeloma.
Blood;
137(17): 2282-2283, 2021 04 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33914079
7.
N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer.
BMC Cancer;
18(1): 939, 2018 Oct 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30285678
8.
EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling.
FASEB J;
31(3): 1011-1027, 2017 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27934660
9.
The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells.
Br J Haematol;
177(3): 423-440, 2017 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28211573
10.
Immunomodulatory Properties of Induced Pluripotent Stem Cell-Derived Mesenchymal Cells.
J Cell Biochem;
117(12): 2844-2853, 2016 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27167148
11.
Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo.
Exp Cell Res;
332(1): 24-38, 2015 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25637218
12.
Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.
Br J Haematol;
171(3): 387-99, 2015 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26194766
13.
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Eur J Haematol;
94(4): 343-54, 2015 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25179233
14.
Engineering interaction between bone marrow derived endothelial cells and electrospun surfaces for artificial vascular graft applications.
Biomacromolecules;
15(4): 1276-87, 2014 Apr 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24564790
15.
Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines.
Leuk Res;
139: 107469, 2024 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38479337
16.
Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma.
Br J Haematol;
161(4): 499-507, 2013 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23438504
17.
Dysregulation of bone remodeling by imatinib mesylate.
Blood;
115(4): 766-74, 2010 Jan 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19890095
18.
Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma.
Mol Oncol;
16(6): 1221-1240, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34245117
19.
Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma.
Cancers (Basel);
12(12)2020 Dec 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33291672
20.
LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.
FASEB Bioadv;
2(6): 339-353, 2020 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32617520